Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting Presentation to Highlight Data for Novel, Orally Available SARM in Patients Recovering from Hip Fracture Surgery |
[17-July-2018] |
SAN DIEGO, Calif., July 17, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the results from the company's Phase 2 study of VK5211 in patients recovering from hip fracture have been selected for presentation as part of the oral plenary session of the American Society for Bone and Mineral Research (ASBMR) 2018 annual meeting. The presentation will highlight the efficacy, safety and tolerability data from the completed Phase 2 clinical trial. The ASBMR 2018 annual meeting is being held September 28 – October 1, 2018 in Montreal, Quebec, Canada. Details of Viking's scheduled presentation are as follows:
VK5211, Viking's lead program for musculoskeletal disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate. The Phase 2 clinical trial was a randomized, double-blind, placebo-controlled, parallel group, international study designed to evaluate the efficacy, safety and tolerability of VK5211 in patients recovering from hip fracture surgery. As previously reported, the top-line data from this study showed that the trial successfully achieved its primary efficacy endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, among patients treated with VK5211, as compared to placebo. The study also achieved important secondary endpoints, demonstrating statistically significant improvements in appendicular lean body mass and total lean body mass compared to placebo. Patients receiving VK5211 also demonstrated numerical improvements in certain exploratory assessments of functional performance. VK5211 demonstrated encouraging safety and tolerability, with no drug-related serious adverse events reported in this study. "We are excited to have the opportunity to present the results of our Phase 2 study at this important conference. The selection of these data for presentation at the ASBMR oral plenary session highlights the importance of novel muscle-targeting therapeutics in areas of high unmet need, such as the hip fracture recovery setting," stated Brian Lian, Ph.D., Viking's chief executive officer. "This challenging population, which includes many older, medically fragile patients, is in need of new treatments that can safely and effectively help improve recovery. We look forward to sharing the detailed results from our study at the conference." About Viking Therapeutics, Inc. Forward-Looking Statements View original content:http://www.prnewswire.com/news-releases/viking-therapeutics-announces-vk5211-phase-2-study-results-selected-for-plenary-oral-presentation-at-asbmr-2018-annual-meeting-300681783.html SOURCE Viking Therapeutics, Inc. | ||
Company Codes: NASDAQ-SMALL:VKTX |
© 2018 PR Newswire. All Rights Reserved.